- Home
- Publications
- Publication Search
- Publication Details
Title
New therapeutic agents for acromegaly
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 12, Issue 2, Pages 90-98
Publisher
Springer Nature
Online
2015-11-27
DOI
10.1038/nrendo.2015.196
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of acromegaly in the era of personalized and predictive medicine
- (2015) Manuel Puig Domingo CLINICAL ENDOCRINOLOGY
- A Structural and Functional Acromegaly Classification
- (2015) Daniel Cuevas-Ramos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
- (2015) Shlomo Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
- (2014) S. J. C. M. M. Neggers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
- (2014) John D. Carmichael et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly: An Endocrine Society Clinical Practice Guideline
- (2014) Laurence Katznelson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
- (2014) A. Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Successful Mortality Reduction and Control of Comorbidities in Patients With Acromegaly Followed at a Highly Specialized Multidisciplinary Clinic
- (2014) Moises Mercado et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacological treatment of acromegaly: its place in the overall therapeutic approach
- (2014) Evgenia Korytnaya et al. JOURNAL OF NEURO-ONCOLOGY
- Mortality in acromegaly reduced with multimodal therapy
- (2014) Nienke R. Biermasz Nature Reviews Endocrinology
- Expert consensus document: A consensus on the medical treatment of acromegaly
- (2014) Andrea Giustina et al. Nature Reviews Endocrinology
- A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
- (2014) Shmuel Tuvia et al. PHARMACEUTICAL RESEARCH
- The role of pasireotide in the treatment of acromegaly
- (2014) Nicholas A Tritos Lancet Diabetes & Endocrinology
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
- (2014) Mônica R Gadelha et al. Lancet Diabetes & Endocrinology
- Emerging drugs for acromegaly
- (2013) Sylvère Störmann et al. EXPERT OPINION ON EMERGING DRUGS
- Octreotide for acromegaly treatment: a reappraisal
- (2013) Andrea Giustina et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
- (2013) Robert R. Henry et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
- (2013) Philippe J. Caron et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Paradigm Shift in the Monitoring of Patients With Acromegaly: Last Available Growth Hormone May Overestimate Risk
- (2013) Mark Sherlock et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
- (2013) Roberto Salvatori et al. Pituitary
- Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
- (2012) S. Tuvia et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
- (2012) A. J. van der Lely et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly
- (2012) Nicholas F. Marko et al. JOURNAL OF NEUROSURGERY
- The changing face of acromegaly—advances in diagnosis and treatment
- (2012) Antônio Ribeiro-Oliveira Jr et al. Nature Reviews Endocrinology
- Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
- (2012) Jessica Brzana et al. Pituitary
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
- (2012) Andrea Giustina et al. PLoS One
- Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres
- (2011) Yun-Seok Rhee et al. AAPS PHARMSCITECH
- DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours
- (2011) U Plöckinger et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Impenetrable barriers or entry portals? The role of cell–cell adhesion during infection
- (2011) Matteo Bonazzi et al. JOURNAL OF CELL BIOLOGY
- Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome
- (2011) John A. Jane et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Medical therapy in acromegaly
- (2011) Mark Sherlock et al. Nature Reviews Endocrinology
- Clinical, quality of life, and economic value of acromegaly disease control
- (2011) A. Ben-Shlomo et al. Pituitary
- Mortality in Patients with Pituitary Disease
- (2010) Mark Sherlock et al. ENDOCRINE REVIEWS
- Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure
- (2010) Manel Puig-Domingo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
- (2010) Maria Fleseriu Pituitary
- A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
- (2009) Peter J. Trainer et al. CLINICAL ENDOCRINOLOGY
- Pituitary-independent effect of octreotide on IGF1 generation
- (2009) Ana Pokrajac et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Acromegaly pathogenesis and treatment
- (2009) Shlomo Melmed JOURNAL OF CLINICAL INVESTIGATION
- A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
- (2008) I M Holdaway et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
- (2008) Giselle F Taboada et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
- (2008) Robert D. Murray et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lipodystrophy in Patients with Acromegaly Receiving Pegvisomant
- (2008) Vivien S. Bonert et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Traffickingin Vitro
- (2008) Sarah Lesche et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly
- (2008) Philippe Chanson et al. Orphanet Journal of Rare Diseases
- Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a
- (2008) F. F. Casanueva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started